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ABSTRACT 
Although the first antibiotic, penicillin, was discovered in 1928 from a microbial natural 
source (a mould, Penicillium notatum), there is earlier evidence of using natural materials 
including moulds and herbs for the treatment of infections. Following the serendipitous 
discovery of penicillin by Alexander Fleming, there have been hundreds of antibiotics (natural, 
semisynthetic and synthetic) discovered for clinical uses. However, the pathogenic organisms 
have developed resistances to existing antibiotics though various mechanisms. Such antibiotic 
resistance or antimicrobial resistance (AMR) is a critical problem of today’s healthcare system 
urging the development of new antibiotics. This chapter has primarily focused into 
antimicrobial compounds developed through natural routes that are currently available as 
antibiotics for clinical uses and/or are at various developmental stages within the drug 
development pipeline for potential treatment of minor and life threatening infections. The 
chapter also provides an overview on the catastrophic problem of antimicrobial resistance, its 
causes, how it spreads as well as modes of developing antimicrobial resistance (AMR). 
Keywords: Antibiotics; antimicrobial agents: antimicrobial resistance; AMR; natural 
products; penicillin; antimicrobial peptides; AMPs 
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1. Introduction  
Infectious diseases are one of the major problems in today’s healthcare system. 
Antibiotics have been used since the second world war for the treatment of various types of 
infections. The term antibiotic is originated from ‘antibiosis’ that simply describes the 
interaction of two or more organisms having at least one being detrimental to other(s). 
Therefore, antibiosis is the process, where one organism in the presence of other organism(s) 
is capable of producing harmful effects to the later organism(s). ‘Antibiotics’ literally describes 
a class of chemical compounds that are responsible for the treatment of infections by inhibiting 
the growth of bacteria or killing bacteria with minimum or no harm to the host. However, a 
more broad term ‘antimicrobial agents’ is used to cover the treatment of infections caused by 
various organisms including bacteria, fungi, protozoa and virus. Moreover, another term ‘anti-
infective agent’ has also been adopted worldwide in the research of antimicrobial drug 
discovery. 
Even though the fortuitous discovery of penicillin in 1928 started the golden era of 
antibiotics, the empirical knowledge of treating wounds with the indigenous herbs and/or 
alternative approaches dates back to the ancient times. Without having any scientific 
knowledge, wounds were treated with spider’s webs, cheese mould or mouldy bread 
ingestion,1 mouldy soybean curd and honey.2 The ancient Egyptians used mouldy bread for 
the treatment of infected wounds, whilst the ancient Chinese used to apply mouldy soybean 
curd to heal boils and managed foot infections by wearing sandals furried with mould.2 In the 
middle ages, honey was used for the treatment of post-arrow wounds.3 During this 
prehistorical era of antibiotics, such treatments were given without any knowledge of bacteria 
or other organisms that caused the infections.  
The search for an effective agent to win in the battle against the bacteria or other 
organisms causing infections started in late nineteenth century. During an experiment with 
Anthrax bacilli in 1877, Pasteur and Joubert noticed that Anthrax bacilli were killed, while 
contaminated with other bacteria. Another experiment in 1901 revealed that a liquid culture of 
Pseudomonas aeruginosa injected to infected rabbits with anthrax recovered them from 
anthrax. Such experimental findings led to the conclusion that the metabolite(s) produced by 
one organism revealed their capabilities to inhibit the growth of other organisms, which 
supported the concept of antibiosis.2 Later in 1910, a Nobel laureate Paul Ehrlich discovered 
an arsenic containing compound known as salvarsan or arsphenamine (1) that became the 
choice of medicine for the treatment of infections including syphilis and trypanosomiasis3 until 
it was replaced by first antibiotic penicillin in 1945.  
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Alexander Fleming, a Scottish Physician and Microbiologist, serendipitously 
discovered penicillin G (2) in 1928. He was working on Staphylococci and stacked some petri-
dishes of Staphylococci on a bench in a corner of his laboratory just before he went for holidays 
in August in 1928. Upon his return from holidays, he noticed that a fungus had contaminated 
a culture plate of Staphylococcus bacterium he had accidentally left uncovered. He also 
noticed that the fungus had inhibited the growth of Staphylococcus bacterium. Fleming grew 
the mould in a pure culture and noticed that it produced a metabolite that responded 
dramatically to treat a number of bacterial infections. He identified the mould as Penicillium 
notatum and named the metabolite as ‘penicillin’, which became the choice of drug to fight 
bacterial infections during that period. Alexander Fleming shared the 1945 Nobel Prize in 
Medicine with Howard Florey and Ernst Chain for their contribution in mass production of the 
first mass-produced antibiotic. Considering the number of lives saved during the end of World 
War II, penicillin was nicknamed 'the wonder drug'.1-3 
 
2 
During the World War II, two more drugs proflavine (3) and prontosil (4) were 
introduced. Proflavine introduced in 1934 was effective in treating infections with deep surface 
wounds, however it was highly toxic. The discovery of prontosil, a sulphur-containing prodrug, 
in 1935 was a real breakthrough for the treatment of systematic infections until the availability 
of penicillin in early 1940s.3 
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2. Antimicrobial resistance  
Since the discovery of penicillin, there have been hundreds of antibiotics discovered 
that are in clinical use to treat infections. Considering the availability of hundreds of antibiotics 
for clinical use, one may raise question why we need new antibiotics. The answer is simple; 
the pathological organisms (bacteria, fungi etc) have developed resistance to various 
antibiotics that have been designed to kill them (bugs) through a number of mechanisms 
(Section 2.2). For example, in 1962, Staphylococcus aureus developed resistance against 
methicillin, which was discovered in 1960. Similarly, because of developed resistance, 
penicillin became ineffective against Streptococcus pneumoniae, and vancomycin against 
Enterococcus faecium,16 years after its discovery (Table 1).4  
Antibiotic resistance (ABR) or more  widely used term antimicrobial resistance (AMR) 
has become an increasing threat to today’s healthcare system because of the unavailability of 
new and safe antibiotics to respond to the demand of antibiotics to treat increased number of 
life threatening infections. AMR infections currently counts more than 67,000 infections in 
Europe with approximately 33,000 death5 costing around €1.1 billion, whilst there are more 
than 2.8 millions infections and more than 35,000 AMR related death certificates currently 
issued in the United State.6 Methicillin-resistant Staphylococcus aureus (MRSA) is a big 
concern as this is a major cause of both healthcare- and community-associated infections 
around the world. It has been estimated there are more than 150,000 patients due to MRSA 
infections in the Europe, which costs approximately €380 million for EU healthcare systems.7 
Pan-European surveillance data on bloodstream infections showed that more than 10% 
Staphylococcus aureus infections in 15 European countries are due to MRSA with some of 
these countries seeing such resistance closer to 50%.8 If no action is taken on tme, it has been 
estimated that AMR will be the leading healthcare problem counting in excess of 10 million 
deaths per year by 2050 costing the world an extra $100 trillion.9  
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Table 1: Antibiotics timeline with dates of discovery and development of resistance4 
Antibiotics  Year 
discovered 
Resistant organisms  Year 
developed 
Penicillin 1941 Penicillin-resistant Staphylococcus aureus 
Penicillin-resistant Streptococcus 
pneumoniae 
Penicillinase-producing Neisseria 
gonorrhoeae 
1942 
1967 
  
1976 
Tetracycline 1950 Tetracycline resistant Shigella 1959 
Amphotericin B 1959 Amphotericin B-resistant Candida auris 2016 
Methicillin 1960 Methicillin-resistant Staphylococcus aureus 1962 
Vancomicin 1972 Plasmid-mediated vancomycin-
resistant Enterococcus faecium 
Vancomycin-resistant Staphylococcus 
aureus 
1988 
 
2002 
Azithromycin 1980 Azithromycin-resistant Neisseria 
gonorrhoeae 
2011 
Ciprofloxacin 1987 Ciprofloxacin-resistant Neisseria 
gonorrhoeae 
2007 
Fluconazole 1990  Fluconazole-resistant Candida  1988 
Daptomycin 2003 Daptomycin-resistant methicillin-
resistant Staphylococcus aureus 
2004 
Ceftazidime-
avibactam 
2015 Ceftazidime-avibactam-resistant KPC-
producing Klebsiella pneumoniae 
2015 
 
2.1  Antimicrobial resistance: its causes and ways it spreads 
 Antimicrobial resistance has become a catastrophic problem for public health in the 
recent years. Widespread uses of antibiotics in medicine, veterinary, agriculture and poultry 
have contributed a lot toward the development of bacterial resistance. The various causes 
beyond the development of resistance to the antibiotics are briefly summarized below.  
2.1.1 Genetic modification of organisms: Antimicrobial resistance can happen naturally 
over time, usually through genetic changes in the bugs. Within our body, there are lots germs- 
some considered as good bacteria (protect the body from infections), other as bad bacteria 
(cause illness through infections) and only few as drug resistant bacteria. When antibiotics are 
taken, they usually kill both bad and good bacteria but cannot do any harm to the drug resistant 
bacteria which in turn are allowed to take over and grow. Some drug resistant bacteria give 
their resistance gene to other bacteria making the latter group of bugs resistant and causing 
the problem worse. Thus, antibacterial resistance occurs naturally through genetic 
modification.10 
2.1.2 Over prescription of antibiotics: Antibiotics have been misused and/or overused 
in humans and animals, which has accelerated dramatically the problem of antimicrobial 
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resistance. Sometimes antibiotics are given for viral infections like cold and flu which do not 
require antibiotics at all. Again, antibiotics are unreasonably given to animals for growth 
promotion and/or prevention of diseases in healthy animals. Antibiotics are also used 
unreasonably in agriculture and for the preservation of poultry products. Such misuses and/or 
overuses of antibiotics cause AMR. 
2.1.3 Gratuitous prescription of broad spectrum antibiotics: Sometimes broad 
spectrum antibiotics are prescribed for the conditions, which could be treated with a narrow 
spectrum antibiotics. Such unjustified prescriptions also contributes towards the development 
of antimicrobial resistance.  
2.1.4 Over-the-counter access to antibiotics and self-medication: Unrestricted access 
to antibiotics and self-medication have made AMR situation even worse in developing 
countries. Patients in some developing countries can buy antibiotics without any prescription 
which enable them to get hold of antibiotics whenever they wish to do so. Thus, they take 
antibiotics without consulting their physicians for conditions, where they should not require 
antibiotics at all. Sometimes they start taking antibiotics but stop before completing the course. 
Such irrational uses of antibiotics are an important route of developing AMR in some 
developing countries. However, AMR awareness activities have recently motivated the policy 
makers in developing countries to think carefully to take initiative to stop antibiotics without 
prescriptions. 
2.1.5 Antibiotics trafficking: Because of easily availability, some people buy antibiotics 
when they travel to developing countries and carry antibiotics with them when they come back. 
Upon return they might consider taking antibiotics for some conditions even through the 
physicians have not prescribed antibiotics. Such ignorance hastens the problems of 
antimicrobial resistance. 
2.1.6 Antimicrobial manufacturing contaminations: During the manufacturing 
antibiotics (both raw materials and finished products) in the Pharmaceutical Industries, 
antibiotics manufacturing wastes and effluents contaminate the environments (air, soil and 
water) and become a major concern for antimicrobial resistance as well.   
Now the next concern regarding AMR is how it spreads. There are two ways of 
spreading AMR- (i) human to human and (ii) animals (poultry) to human. If a person takes 
antibiotics for the treatment of infection, but unfortunately develops resistant bugs, then the 
person may stay at home or gets care in hospital, care home or other inpatient facilities. If s/he 
stays at home, then AMR may spreads to family members and/ or friends and ultimately to the 
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community. At hospital or inpatient facilities, the infected person spreads AMR to doctors, 
nurses and other health professionals and thereby to the community. 
When animals (common poultries) are given antibiotics but developed resistant 
bacteria in their guts, they spread these resistant gene to people when the meats from animals 
with drug-resistant bacteria are not handled properly and/ or cooked properly. Sometimes, 
fertilizers or water containing animal faeces and drug-resistant bacteria are used to grow 
vegetables and crops and thereby, such drug-resistant bacteria can be transferred to 
vegetables and crops. Ultimately, such drug-resistant bacteria spreads to humans when these 
vegetables and crops are consumed. 
2.2  Mechanisms of antimicrobial resistance  
 Although several classes of antibiotics are in clinical uses and act in different modes 
of action, however the organisms have developed resistance to existing antibiotics using one 
or more of the following mechanisms.  
2.2.1 Enzymatic inactivation of the antibiotics: This is the most common mechanism of 
developing resistance to several antibiotics such as penicillins, cephalosporins, 
chloramphenicol and aminoglycosides. This is simply happens when bacteria (both Gram-
positive and Gram-negative) are capable of producing enzymes that inactivate or destroy the 
antibiotics. For example, -lactamases enzymes produced by Staphylococci and also, 
sometime Gram-negative bacteria, cleave the -lactam ring of penicillins and 
cephalosporins.11,12 Some of these -lactamases encoded by transposons may transfer 
resistance genes to other antibiotics as well. Another enzyme, chloramphenicol 
acetyltransferase, produced by both Gram-positive and Gram-negative bacteria inactivate 
chloramphenicol.11 Similarly, kinases and other enzymes produced by both Gram-positive and 
Gram-negative bacteria can inactivate aminoglycosides by enzymatic reactions like 
phosphorylation, adenylation or acetylation.11,13   
2.2.2 Alteration of antibiotic target sites: A large number of target sites alterations 
mechanisms are also found in clinical isolates. Chromosomal mutations can alter 30S subunit 
of ribosome which is the binding site protein for aminoglycoside and thereby, inactivate the 
antibiotic. Similarly, erythromycin may be inactivated  through a plasmid-led changes on the 
50S subunit of ribosome. Rifampicin resistance was reported to be related to the DNA-
dependent RNA polymerase alteration.11,13 Besides the enzymatic cleavages, resistance to β-
lactam antibiotics is also conferred by target modification through a mutated chromosomal 
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gene as seen in MRSA strains where its exogenous penicillin binding protein (PBP; its 
transpeptidase domain) is insensitive to the action of several different β-lactams. 11,13  
2.2.3 Decreased intracellular accumulation and/or efflux of antibiotics:  This is 
considered as second common modes of developing antibiotic resistance in clinical strains. 
Decreased permeability is prominent in Gram-negative bacteria because of the presence of 
the additional outer membrane favouring a permeability barrier and offering an essential 
mechanism for protection against hydrophilic antibiotics like vancomycin.14 Plasmid-
determined inhibition of the porin genes and/or changes in their expression have been evident 
to further impact the susceptibility of Gram-negative bacteria to hydrophilic antibiotics.15 Both 
Gram-positive and Gram-negative bacteria have also been reported to exhibit different types 
of active efflux pumps belonging to one of the five families: ABC, MFS, RND (Resistance-
Nodulation-Division), MATE (Multidrug and Toxin Extrusion), and SMR (Small Multidrug 
Resistance).16 The emergence of resistance to fluoroquinolone in Streptococcus pneumoniae has 
been evident by active efflux pumps.17  
2.2.4 Modification of metabolic pathways or bypassing antibiotic inhibiting reactions: 
Plasmid mediated sulphonamide resistance in many bacteria appears due to the production 
of dihydropteroate synthetase with low affinity for antibiotic but no alteration in the affinity for 
PABA.11 So sulphonamide resistance bacteria do not use PABA to synthesize nucleic acid 
and folic acid.18 
3. Antimicrobial natural products  
Since the dawn of human civilisation, human beings have depended on natural 
resources, mostly plants and moulds, for the treatment of various types of diseases including 
infections. Although the majority of the today’s antibiotics are derived from microbia l sources 
or their semisynthetic analogues, scientists around the globe have continued to carry out 
systematic research on microbes as well as on medicinal plants, marine organisms and 
animals for the discovery of new antibiotics. This section highlight key antimicrobial 
compounds isolated from natural sources covering microbes,  medicinal plants, marine 
organisms and animals. 
3.1 Antimicrobial natural products from microorganisms  
Penicillin G (benzylpenicillin, 2) and its semisynthetic analogue penicillin V 
(phenoxymethylpenicillin, 5) belong to the class of -lactam antibiotics that act by inhibiting 
the synthesis of the bacterial cell wall peptidoglycan. These are active against a wide range 
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of organisms and considered as drugs of first choice for various infections. However, the poor 
absorption in the gastrointestinal tract and susceptibility to the enzyme -lactamase are their 
main shortcomings.  
 
5 
A number of further semi-synthetic penicillins such as methicillin, flucloxacillin, 
ampicillin and amoxycillin were developed by simple modification of side chains attached to 
the penicillin nucleus (R in Figure 1). Among these, methicillin and flucloxacillin are -
lactamase resistant penicillins, while ampicillin and amoxycillin provide broad spectrum 
activity.19 
Cephalosporins also belonging to -lactam antibiotics were originated from the fungus 
Cephalosporium. Discovered in 1945 by an Italian pharmacologist Giuseppe Brotzu, 
cephalosporins are broad spectrum antibiotics used for the treatment of a number of infections 
including septicaemia, pneumonia, meningitis, biliary-tract infections, peritonitis, and urinary-
tract infections. Cephamycins, structurally similar to cephalosporins, are also classified as -
lactam antibiotics having similar mechanism of action as penicillins which were isolated from 
the microorganism Streptomyces, the largest genus of Actinobacteria. Various semisynthetic 
cephalosporins were developed by modifying the two side chains (R1 and R2 in Figure 1) of 
cephalosporin nucleus. 19,20 
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Figure 1: General structures of penicillins (6) and cephalosporins (7) 
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Vancomycin, a glycopeptide antibiotic with seven peptides present in the molecule, 
was discovered a Pharmaceutical company Eli Lilly in 1952 from a soil bacterium, 
Streptomyces orientalis.21 It works by inhibiting the bacterial cell wall synthesis in the last stage 
through binding to the terminal D-alanyl-D-alanine of peptidoglycan precursors. This is used 
for the treatment of MRSA and some other bacteria resistant to -lactam antibiotics. Its clinical 
uses also include the treatment of infections related to Pseudomonas colitis.21 
Tetracyclines (8) discovered in the 1940s are a class of broad-spectrum antibiotics, 
which following entry into the organisms act by interfering the bacterial protein synthesis. They 
consist of four six-membered rings (designated as A, B, C and D) fused linearly to form 
tetracycline (four cyclic) nucleus to which various functional groups and/ substituents are 
attached. As they contain a number of keto groups in the molecules they are also considered 
a class of compounds known as polyketides. Members belonging to this antibiotic class 
include tetracycline, oxytetracycline, chlortetracycline, demeclocycline, minocycline, 
doxycycline, methacycline and lymecycline. Among these, chlortetracycline and 
oxytetracycline are the first two members of natural tetracyclines both discovered in the 1940s 
from the filamentous bacteria Streptomyces aureofaciens and S. rimosus, respectively. Other 
naturally occurring antibiotics in the class such as tetracycline were isolated from S. 
aureofaciens, S. rimosus, and S. viridofaciens and demethylchlortetracycline from S. 
aureofaciens.22  
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Semi-synthetic tetracyclines such as doxycycline, minocycline, methacycline and 
lymecycline are produced from natural tetracyclines by simple modifications on the functional 
groups and/or substituents. Tetracyclines are used for the treatment of a wide range of 
microorganisms including both Gram-positive and Gram-negative bacteria, Chlamydia, 
Rickettsia, Mycoplasma and protozoa.22 Because of their capabilities of reacting with chelating 
ions such as calcium, magnesium, aluminium and iron forming non-absorbable complexes, 
their absorption is reduced significantly in the presence of milk, iron preparations and antacids. 
Accordingly, patients are advised not to take oral tetracyclines with milk, antacids and iron 
preparations to avoid the consequence of forming non-absorbable complexes.  
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Chloramphenicol (9), an amphenicol, was isolated from a soil-dwelling bacterium, 
Streptomyces venezuelae in 1947 and its chemical structure was confirmed in 1949.23 
Following its discovery, it was manufactured in large scale through synthetic route and is 
considered as the first synthetic antibiotic as well. It acts by interfering the protein synthesis of 
bacteria by binding to the 50S ribosomes. It has a wide range of antimicrobial activity including 
Gram-positive and Gram-negative bacteria as well as rickettsia. Chloramphenicol ointment is 
widely used for the treatment of eye infections.24 Together with antibiotics such as 
amphotericin B (10), griseofulvin (11) and streptomycin (12), chloramphenicol (9) is in the 
World Health Organisation’s List of Essential Medicines, the safest and most effective 
medicines needed in a health system.25 However, its most common side effect is idiosyncratic 
depression of bone marrow. It also causes grey baby syndrome in young children so it should 
administered to new-borns with great care by regular monitoring its plasma level.24 
-
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Amphotericin B (10) is an antifungal agent derived from the culture of Streptomyces 
nodosus in 1955.26  This is a polyene macrolide that acts on the fungal cell membrane and 
binds with its cell membrane component ergosterol forming large pores leding to the gross 
disturbance in monovalent ion balance with ultimate leakage of intracellular K+, Na+, H+ and 
Cl- resulting in fungal cell death. This is a preferred antibiotic for the treatment for disseminated 
infections caused several fungi and yeast including Aspergillus and Candida.27  
Griseofulvin (11), discovered in 1939 from a culture of Penicillium griseofulvum,28 is a 
narrow spectrum antifungal antibiotic that works by binding to fungal microtubules and thus 
inferring fungal mitosis. It is administered orally for the treatment of dermatophytosis including 
the fungal infections of skins, scalp and nails when the local/ topical antifungal agents become 
ineffective.  
Streptomycin (12) belongs to the aminoglycoside class of antibiotics, and was 
discovered in 1943 from a culture of soil actinomycete, Streptomyces griseus.29 Kanamycin 
(also known as kanamycin A)  is another aminoglycoside antibiotic which was isolated in 1957 
from the soil actinomycete, Streptomyces kanamyceticus.29 Chemically, these 
aminoglycosides contain aminated carbohydrate rings connected to dibasic cyclitol through 
glycosidic linkage. Upon uptake to susceptible organisms, these antibiotics bind to the 
bacterial 30S ribosomal subunit and thereby disrupt the initiation and elongation steps in 
protein synthesis. As broad spectrum antibiotics, these are used for the treatment of several 
life threatening infections including tuberculosis, sepsis, endocarditis, brucellosis, and severe 
urinary tract infections.30 
Echinocandin B (13) is an antifungal agent which is  composed of a ring of six amino 
acids connected to a long-chain lipophilic side chain. It was discovered in 1974 from a culture 
of Aspergillus nidulans.28,31 It acts by inhibiting the synthesis of 1,3--glucan, an essential 
component of fungal cell wall structure. It is fungicidal against some yeasts, mostly Candida 
species. Bacitracin is another similar polypeptide antibiotic composed of 11 amino acids 
(seven as part of ring and four in the side chain) was discovered in 1945 from a culture of the 
licheniformis group of  Gram-positive bacterium Bacillus subtilis.32 It is a narrow-spectrum 
antibiotic used for the treatment of infections caused by Gram-positive bacteria, especially 
those that cause skin infections specially those caused by small cuts, scrapes, or 
burns. It  stops the growth of certain bacteria by inhibiting the bacterial cell and peptidoglycan 
synthesis.32 
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Polymyxins are cationic polypeptides composed of a cyclic heptapeptide plus a 
tripeptide side chain acylated at the N terminus by a fatty acid tail. Polymyxin B was first 
isolated in 1947 from a culture of a Gram-positive bacterium, Bacillus polymyxa.33  Colistin 
(also known as polymyxin E) is a polypeptide antibiotic that was originally isolated in 1947 
from the soil bacterium Paenibacillus polymyxa subsp. colistinus. 34 Colistin and polymyxin B 
are used for the treatment of infections caused by Gram-negative bacteria and act by breaking 
down the cytoplasmic membrane causing the ultimate death of bacterial cell.33,34 
Neomycins (e.g., neomycin B, 14 and neomycin C, 15) are amino glycoside antibiotics 
comprising amino sugars connected through glycosidic linkages. The first member of this class 
was discovered in 1949 by the microbiologists Waksman and Lechevalier from a culture of the 
bacterium, Streptomyces fradiae.35 This antibiotic is available in a number of topical 
preparations such as creams, ointments, and eyedrops.  It acts by inhibiting the protein 
synthesis through binding with 30S ribosome causing genetic disruption. It also act by 
interfering the bacterial enzyme DNA polymerase.35  
Nystatin (16), structurally related to amphotericin B, is an antifungal agent, which was 
isolated from the culture of actinomycetes, Streptomyces noursei, found in the soil of a dairy 
farm in USA.36 Like other antifungal agent such as amphotericin B, it acts by binding with 
fungal cell membrane component, ergosterol, forming large pores in the membrane leading 
the leakage of K+ and ultimate death of fungal cell. It is given for the treatment of fungal 
infections caused mostly by Candia including esophageal candidiasis, thrush and vaginal 
infections. 37  
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14 R = CH2NH2; R’ = H 
15 R = H; R’ = CH2NH2  
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Erythromycin (17), a macrolide antibiotic, was discovered in 1952 from the culture of 
bacterium Saccharopolyspora erythraea.38 It offers bacteriostatic activity by inhibiting the 
protein synthesis through binding with bacterial 50S subunit of rRNA, and is widely used for 
the treatment of chest infections (pneumonia), skin diseases (acne) and sexually transmitted 
diseases.38 
Rifamycins (A-E), a group of structurally related secondary microbial metabolites, were 
discovered in 1957 from a product of fermentation from the Gram-positive 
bacterium Amycolatopsis mediterranei (also known as Streptomyces mediterranei).39 Among 
these metabolites, rifamycin B (18) was isolated in pure form but with poor activity, but could 
easily be oxidized to more active form, rifamycin S, which was further modified to produce  
clinically relvant rifamycin SV (19), the first antibiotic used intravenously for the treatment of 
tuberculosis. Because of its high affinity to the prokaryotic enzyme, RNA polymeraze, 
rifamycins act by inhibiting the bacterial DNA-dependent RNA synthesis.40 
Like neomycins, gentamycin (20) and ribostamycin (21) are two other popular 
aminoglycoside antibiotics. Gentamicin (20) was identified in 1962 from the fermentation broth 
of a bacterium, Micromonspora purpurea.41 This bactericidal antibiotic acts by binding the 30S 
subunit of the bacterial ribosome and thereby, inhibiting bacterial protein synthesis. It is active 
against a wide range of bacterial infections including urinary tract infections, respiratory tract 
infections, blood, bone and soft tissue infections.41 On the other hand, ribostamycin (21) was 
first isolated in Japan in 1970 from the fermentation broth of a soil bacterium, Streptomyces 
ribosidificus.42 Like other aminoglycosides, it also acts by inhibiting protein synthesis through 
binding with 30S subunit of bacterial ribosome.43 
Mupirocin (22) was initially isolated in 1971 from the culture of a rod-shaped Gram-
negative bacterium, Pseudomonas fluorescens.44 It works by reversibly binding to the isoleucyl 
t-RNA synthetase in Staphylococcus aureus and Streptococcus and thereby inhibiting the 
protein synthesis. This topical antibiotic is used for the treatment of skin infections such as 
impetigo and folliculitis as well as for MRSA.44  
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Among the recently introduced antibiotics, daptomycin, a lipopeptide antibiotic, was 
isolated from the soil bacterium, Streptomyces roseosporus.45 It was approved in 2003 by the 
FDA for the treatment of complicated skin and soft tissue infections. It acts by disrupting 
multiple aspects of bacterial cell membrane function. Upon ingestion, it attacks the cell 
membrane (phosphatidylglycerol) forming holes that leak ions like K+ and ultimate death of 
bacterial cell.45 Platensimycin (23) and platencin are relatively recent novel antibiotics which 
were isolated from a bacterium Streptomyces platensis by using an antisense whole-cell 
differential sensitivity assay, where control organisms were compared to cells expressing fabF 
antisense RNA.46 Both compounds a 3-amino-2,4-dihydroxy-benzoic acid and a different 
unusual diterpene (tetracyclic enone acid in platensimycin, while a tricyclic enone acid in 
platencin). They are potent and non-toxic natural products with potent activity against Gram-
positive pathogens, including antibiotic-resistant strains and Mycobacterium 
tuberculosis.47 Because of their unique structural features and promising antibacterial activity, 
they have been a breakthrough in the searches for novel antibiotics. Platensimycin was first 
isolated by the Merck group.  
 
23 
Lactic acid bacteria are good gut bacteria that produce secondary metabolites with 
potential antimicrobial activity. For example, nisin, which is a polycyclic antibacterial peptide 
composed of 34 amino acids in the molecule, was produced from the culture of a Gram-
positive bacterium Lactococcus lactis that has been has been extensively used in the 
production of buttermilk and cheese. It is used as a food preservative because of its 
bactericidal activities against Gram-positive as well as spore forming food-borne bacteria 
including S. aureus and Listeria monocytogenes.48 In the research laboratories, it is very useful 
as a selective agent in microbiological media for the isolation of gram-negative bacteria, yeast, 
and moulds. Reuterin (3-hydroxypropionaldehyde; 24),49 reutericin 650 and reutericyclin51 are 
produced by Lactobacillus reuteri and have a broad spectrum activity against food-borne 
pathogens and spoilage organisms. Reuterin (24), a simple aldehyde, in combination with 
nisin offer synergistic antimicrobial activity and reduce significantly the growth of Gram-
positive Staphylococcus aureus, Lactobacillus monocytogenes, and Gram-negative E. coli 
and S. Typhimorium. Reuterin inhibits the growth of some harmful bacteria (both Gram-
positive and Gram-negative) as well as some fungi, yeasts and protozoa. L. reuteri secreting 
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sufficient amounts of reuterin to achieve the desired antimicrobial effects is capable of 
eliminating gut invaders without harming other gut microbiota.49 
 
24 
The above examples show the histrory and progression of development of antibiotics 
from microbial soirces throughout the past several decades, but in the recent past, there are 
hardly any new antiobiotics reported from microbial sources, which have become commercialy 
available for the treatment of infections. However, this does not mean the the search for new 
antibiotics or antimicrobial agents has stopped. In fact, there are several papers published in 
recent years describing various antimicrobial compounds from microbial sources with diffrent 
levels and spectrum of activities. A cultural broth of Pseudomonas sp. Ki19. was reported to 
produce four dialkyl resorcinols, 2-butyl-5-propylresorcinol (25), 2-hexyl-5-methylresorcinol 
(26), 2-hexyl-5-propylresorcinol (27), and 2-hexyl-5-pentylresorcinol (28) with antimicrobial 
activity against S. aureus (MIC 10 g/mL), Aspergillus fumigatus (MIC = 50 g/mL) and 
Fusarium culmorum (MIC = 50 g/mL).52 
 
25 R = Butyl; R’ = Propyl 
26 R = Hexyl; R’ = Methyl 
27 R = Hexyl; R’ = Propyl 
28 R = Hexyl; R’ = Pentyl 
A fungus belonging to the genus Phoma produced three acetylenic acids, phomallenic 
acids A–C, which exhibited potent antibacterial activity against wild-type S. aureus with MICs 
in the range 3.9–7.8 g/mL, with phomallenic acid C being the most active one, superior to 
commonly used FabF inhibitors such as cerulenin and thiolactomycin.53 Ten-membered 
macrolides, phomolides A (29) and B (30), were isolated from the cultural broth of Phomopsis 
sp. hzla01-1 which revealed significant antimicrobial activities against Escherichia coli 
CMCC44103, Candida albicans AS2.538 and Saccharomyces erevisiae ATCC9763 (MICs  5–
10 g/mL).54  
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A culture broth of Lysobacter sp. produced antimicrobial polypeptides (AMPs), 
tripropeptins A-E and Z (MICs 0.39–12.5 g/mL). Among these polypeptides, tripropeptins C 
and D displayed strong activities against Gram-positive bacteria, including both MRSA and 
vancomycin-resistant Enterococcus.
55 The culture broth of a cyanobacterium belonging to the 
genus Hassallia yielded braod-spectrum antifungal glycosylated lipopeptide hassallidins A and 
B (MICs of 8-16 g/mL against 10 species of Candida).56,57 The isolation of an unusual 
depsipeptide, teixobactin (31), from a soil bacterium is  the most recent breakthrough in the 
search for antimicrobial drugs because of its intrinsic antibacterial activity, structural novelty 
and method of identification involving the culture production in natural soil environment. The 
hypothesis for thus drug discovery was based on that fact that the uncultured bacteria making 
up approximately 99% of all species in external environments could be an untapped source 
of new antibiotics. Accordingly, teixobactin (31) has been discovered through a screen of 
uncultured bacteria using a new device, i-Chip sealed with semi-permeable membranes.58 It 
showed potent in vitro antimicrobial activity against Gram-positive bacterial strains including 
Staphylococcus aureus, Bacillus anthracis, Enterococci species and Clostridium difficile as 
well as Mycobacterium tuberculosis. It was also found effective in vivo against methicillin-
resistant  Staphylococcus aureus and Streptomyces pneumoniae in mice model. This 
compound was demosntrated to act by inhibiting the bacterial cell wall synthesis by binding at 
both lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid).58  
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The first synthetic analogue of natural teixobactin  was synthesized by substituting the L-allo-
enduracididine residue with the naturally occurring L-arginine which exhibited the antibacterial 
activity against Gram-positive bacteria similar to that of teixobactin.59 
Six-membered cyclic depsipeptides, enniatins [A (32), A1, B, B1 and B2], were isolated 
from the methanolic extract of the endophyte Fusarium tricinctum Corda. The methanol 
extract of F. tricinctum displayed mild antibacterial and antileishmanial activities as well as 
inhibition of the activity of thioredoxin reductase enzyme of Plasmodium falciparum.60 
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A co-cultivated fungus, Coprinopsis cinereal, produced a olypeptide antibiotic, copsin, 
which revealed its bactericidal property against a diversity of Gram-positive bacteria, including 
human pathogens such as Enterococcus faecium and Listeria monocytogenes.61 Similarly, 
albicidin, a unique polyaromatic oligopeptide, mainly composed of p-aminobenzoic acids, was 
reported from the sugarcane invading bacterium Xanthomonas albilineans. This is a potent 
DNA gyrase inhibitor against a range of both Gram-positive and Gram-negative bacterial 
strains.62 Three highly potent novel antibacterial compounds, the myxobacteria-derived 
cystobactamids 1-3, were isolated from Cystobacter sp.63 These are inhibitors of bacterial 
DNA gyrase (type II topoisomerase) and revealed  activity against E. coli, A. baumannii, E. 
faecalis, S. aureus and S. pneumonia with very lows MICs.63 Despite promising antimicrobial 
activities of recently repprted compounds, none of then has entered any proper clinival trials 
or extensive in vivo studies involving various animal models. 
 
3.2 Plant derived antimicrobial natural products  
Plants are main natural remedies which have been used for centuries for the treatment of 
various human ailments including infections. They are well known for the production of 
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biologically active compounds and have played key role in modern drug discovery (See 
Chapter 1 Medicinal Natural Products – An Introduction by Nahar and Sarker). A huge number 
of drugs in clinical uses today are either derived from plants or synthetic analogues of plant 
derived secondary metabolites. Some examples of such plant derived medicines include 
anticancer drugs like taxol, vinblastine, vincristine; antimalarial drugs like quinine, quinoline, 
artemisinin; analgesic drugs like morphine, codeine, eugenol; and cardioactive drugs like 
digoxin, digitoxin, lactoside C; CNS stimulants like caffeine; laxatives like sennosides and so 
many other drugs.64 However, medicinal plants have been underexploited to some extent as 
a source of antimicrobial lead compounds. Nevertheless, there has been a significant body of 
ongoing research involving medicinal plants that have traditinally been used  for the treatment 
of various infections in the traditional medicines including thr Ayurvedic system65 and the 
Traditional Chinese Medicine (TCM).66 The antimicrobial property of plants is associated with 
and a part of their defense mehcanisms against micorbial attacks. Extensive phytochemical 
and/or bioassay directed syudoes on various medicinal plants have led to the characterization 
of a wide range of antimicrobial compounds. This section covers key plant-derived compounds 
with potential antimicrobial activity.  
Aromatic medicinal plants, such as cinnamon, clove, cilantro, coriander, fennel, 
oregano, peppermint, rosemary, thyme etc. are good sources of essential oils, which have 
been well documented for thier abilities to inhibit the growth of a variety of microorganisms.67 
Such naturally occurring essential oils act as preservatives (inhibit the growth of 
microorganisms) and flavouring agents and are sometimes incorporated in the food products. 
Chemically, these essential oils are terpenes, predominately mono- and sesqui-terpenes. For 
example, the major compounds present in cinnamon, Cinnamomum zeylandicum, and clove, 
Syzgium aromaticum, are trans-cinnamaldehyde (33) and eugenol (34), respectively; both are 
simple monoterpenes. Such essential oils can inhibit the growth of moulds, yeasts, and 
bacteria. Cinnamon and clove oils added at a concentration of 2% in potato dextrose agar 
(PDA) displayed complete inhibition of the growth of mycotoxigenic moulds such as 
Aspergillus flavus, A. parasiticus, A. ochraceus, Penicillium sp. M46, P. roqueforti, P. patulum, 
and P. citrinum for a period of up to 21 days.68 Both oils have also been documented for their 
ability to inhibit the growth of many microorganisms including Lactobacillus sp., Bacillus 
thermoacidurans, Salmonella sp., Coryne bacterium michiganense, Pseudomonas 
striafaciens, Clostridium botulinum, Aspergillus sp., Canninghamella sp., Fusarium sp., and 
Penicillium sp.69 The cinnamon oil was reported to inhibit the growth of A. flavus, A. parasiticus, 
A. ochraceus, and Fusarium moniliforme on PDA at very low concentration (500 ppm).70 
Eugenol, the main constituent of clove oil, has been used widely in perfumeries as flavouring 
agents, and also as an analgesic, local anaesthetic, anti-inflammatory, and antibacterial 
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agent.71 It is used as an important constituent in the formulation of a paste or mixture as dental 
cement, filler, and restorative material local antiseptic and anaesthetic in dentistry. Clove has 
also been reported to have strong antibacterial activity against S. aureus, Escherichia coli and 
Listeria monocytogenes with MICs in the range of 0.3-2.5 g/mL.72 
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An antibacterial metabolite known as hypericin (35) has been isolated from St John’s 
Wort (Hypericum perforatum), a herb widely used in the Western Herbal Medicine for the 
treatment of depression. This compound exhibited highly promising antibacterial activity 
against methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant variants 
reported with MICs  of 0.1 µg/mL.73 Medicinal Phytochemistry group at the UCL School of 
Pharmacy led by Professor Simon Gibbons74 carried out extensive bioassay directed 
investigation on the genus Hypericum to explore antibacterial compounds with potential 
activity against a number of clinical isolates of methicillin resistant S. aureus (MRSA) strains. 
Bioassay-guided investigations into several Hypericum species led to the isolation of new 
acylphloroglucinols,74-76 nor-lignans77 and xanthone78 with significant activity against S. 
aureus. Hyperenone A (36), a constituent of H. acmosepalum,74 showed antibacterial activity 
against Staphylococcus aureus and M. tuberculosis as well as the inhibition of the adenosine 
triphosphate-dependent MurE ligase of M. tuberculosis, a crucial enzyme for peptidoglycan 
biosynthesis. An acylphologlucinol, (S,E)-1-(2-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-4,6-
dihydroxyphenyl)-2-methylbutan-1-one (trivial name, olympicin A) was isolated from H. 
Olympicum with promising (MICs of 1 µg/mL) activity against a panel of clinical isolates of 
multidrug-resistant (MDR) and methicillin resistant Staphylococcus aureus.73 Such high 
antibacterial activity inspired the group to carry out the total synthesis of olympicin A as well 
as to make its analogues to fit into structure activity relationship (SAR) study. Olympicin A was 
synthesized in large scale and a number of its analogues were prepared by simply modifying 
two  substituents. Among the analogues, the synthetic compound prepared by substituting 
gerenyl side chain with octyl group revealed same or 2-fold activity compared to natural 
olympicin A.79  
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Like phloroglucinols, the antimicrobial activities of phenolic compounds have also been 
extensively studied. For example, eupomatenoid-3 (37), eupomatenoid-5 (38), eupomatenoid-
6 (39) and conocarpan (40), isolated from Piper regnellii showed antibacterial activity. Among 
them, compounds 38 and 39 exhibited significant antibacterial activity against Staphylococcus 
aureus, Bacillus subtilis, and B. subtilis with MICs of 1.56- 6.25 µg/mL.80  Similarly, several 
antimicrobial isoflavanones including 5,7-dihydroxy-2’- methoxy-3’,4’-
methylenedioxyisoflavanone and 4’,5-dihydroxy-2’,3’-dimethoxy-7-(5-hydroxyoxychromen-
7yl)-isoflavanone were reported from a perennial herb, Uraria picta Desv., which has been 
traditionally used as an antidote to the venom of a dangerous Indian snake, Echis carinata.81 
These isoflavanones showed the antimicrobial activity against bacteria and fungi with MICs in 
the range of 12.5-100 µg/mL. 81 Flemingia paniculata several antimicrobial compounds 
including a simple salicylic acid derivative, 2-carboxy-3-(2-hydroxypropanyl)phenol,3-hydroxy-
4-methoxycinnamaldehyde and several isoflavones including 5,7,4’-trihydroxy-8-(1,1-
dimethyl-prop-2-enyl)-isoflavone, 5,7,2’,4’-tetrahydroxy-8-(1,1-dimethyl-prop-2-enyl)-
isoflavone  and 5,2’,4’-trihydroxy-4”,4”,5”()-trimethyl-4”,5”-dihydrofurano-(7,6,2”,3”)-
isoflavone82 with significant activities (MICs 1.57-200 g/mL).83 The highest potency (MIC 1.57 
g/ml; 0.005 mmol) was exhibited by 5,7,4’-trihydroxy-8-(1,1-dimethyl- prop-2-enyl)-isoflavone 
(41), against S. aureus. 83 
Quinones are well documented for their biological properties including antimicrobial 
activity. Bouldiaquinone, 2-acetylfuro-1,4-naphthoquinone, 2-hydroxy-3-methoxy-9,10-dioxo-
9,10-dihydroanthracene-1-carbaldehyde and lapachol (42) were reported from the root bark 
of Newbouldia laevis with broad-spectrum in vitro antimicrobial activity against six Gram-
positive and twelve Gram-negative bacterial species, as well as Candida strains with MIC 
values in the range 0.076–9.76 g/mL.
84 Aerial part of Saprosma fragrans  was reported to 
produce 3,4-dihydroxy-1-methoxyanthraquinone-2-carboxaldehyde and damnacanthal (43), 
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which exhibited antifungal activities against Trichophyton mentagrophytes, Cryptococcus 
neoformans, Sporothrix schenckii and T. mentagrophytes (MIC = 1.56-12.5 g/mL).
85  
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Many plant extracts containing steroidal saponins possess antimicrobial propery. For 
example, the flower of Allium leucanthum produced aginoside and (25R)-5-spirostan-3,6-
diol-3-O-{-D-glucopyranosyl-(1→2)-O-[-D-xylopyranosyl-(1→3)]-O--D-glucopyranosyl-
(1→4)- -D-galactopyranoside}, which showed in vitro antifungal activity against seven 
Candida strains with MFCs in the range of 6.25-12.5 g/mL.
86 Tigogenin 3-O--D-
xylopyranosyl-(1→2)-[-D-xylopyranosyl(1→3)]--D-glucopyranosyl-(1→4)-[-L-
rhamnopyranosyl-(1→2)]--D-galactopyranoside and tigogenin 3-O--D-glucopyranosyl-
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(1→2)-[-D-xylopyranosyl-(1→3)]--D-glucopyranosyl-(1→4)--D-galactopyranoside were 
isolated from Tribulus terrestris, and showed significant activity against C. albicans (MIC = 10-
2.3 g/mL) and Cryptococcus neoformans (MIC = 1.7-6.7 g/mL).
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 Another steroidal saponin, 
dioscin, isolated from the rhizomes of Smilacina atropurpurea, showed antifungal against C. 
albicans and C. glabrata (MFCs 5.0 g/mL).
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These are just a few examples of plant-derived antimicrobial compounds from several 
that have been reported in recent years. However, their in vitro antimicrobial efficacy is 
nowhere near any well-known antimicrobial agents obtained from microbial sources, and none 
of these compounds have been tested in vivo.  
3.3 Antimicrobial natural products from marine organisms 
The sections above have documented some examples of antimicrobial compounds 
predominantly from terrestrial organisms. However, various organisms from marine origin, 
have recently been shown as potential sources of new compounds with various therapeutic 
applications, including eeficacy against infections. During last few decades there have been 
an incredible amount of research carried out on marine organisms and phytoplankton to 
explore the bioactive compounds to be considered as lead compounds in drug discovery 
including antimicrobial compounds. The marine environment is a rich source for unique 
actinomycete bacteria, which have produced thousands of metabolites with significant 
biological activity.89 Many of the marine-derived actinomycetes have been produced 
structurally diverse secondary metabolites with promising anticancer properties.90 With 
regards to the discovery of antibiotics, marine actinomycetes are less developed, however the 
isolation of promising antibiotics such as anthracimycin has inspired natural product chemists 
to explore this source further.91 Anthracimycin (44) is a polyketide antibiotic isolated first in 
2013 from a marine actinomycete of the genus Streptomyces (strain CNH365) collected off 
the shore of Santa Barbara at USA.91  Another strain of Streptomyces (strain T676) isolated 
off the coast of St. John's Island, Singapore, also produced anthracimycin.92 However, the 
research on marine actinomycetes for bioactive lead compounds started far earlier.  Five 
structurally unique depsipeptides, salinamides A-E, were reported from a marine-derived 
Streptomyces sp. (strain CNB-091), which showed significant antibacterial and anti-
inflammatory properties.93 Subsequently, salinamide A exhibited significant inhibitory activity 
against RNA polymerase (RNAP) from Gram-positive and Gram-negative bacteria.94 Further 
research was carried out on the Streptomyces sp. CNB-091 resulting in the isolation of  
salinamide F, from the ethyl acetate fraction, which also revealed significant RNAP-inhibitory 
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activity against S. aureus (IC50 4 μM) and E. coli (IC50 4 μM) as well as antibacterial activity 
against Enterococcus faecalis (MIC 12.5 μg/mL), S. aureus (MIC100 μg/mL), H. influenzae 
(MIC 12.5 μg/mL), Neisseria gonorrhoeae (MIC 25 μg/mL), Enterobacter cloacae (MIC 50 
μg/mL) and E. coli (MIC 0.20 μg/mL).95  
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Cyclic depsipeptides, ulleungamides A and B,96 were isolated from cultures of 
Streptomyces sp. which showed limited activity against Staphylococcus aureus and 
Salmonella typhimurium but no cytotoxicity. The antibacterial activity was tested using disc 
diffusion method. Zones of inhibitions of these two compounds against the above two 
organisms were found in the range of 9-16 mm compared to 20-25 mm of a positive standard, 
tetracycline. Eeudesmene-type sesquiterpenes, kandenols A-E (45-49) 97 from the culture 
broth of  Streptomyces sp. (strain HKI0595) showed weak to moderate antimicrobial activities 
against Bacillus subtilis ATCC 6633 and Mycobacterium vaccae.97   
 
45 R = OH, R’ = H 
46 R = OH, R’ = OH 
47 R = OH, R’ = O-OH 
48 R = H, R’ = O-OH 
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Naturally occurring brominated diterpenes with tetracyclic skeletons, ioniols I (50) and 
II,98-100 were isolated from Sphaerococcus coronopifolius, a marine sponge collected from the 
rocky coasts of Corfu island in the Ionian Sea. These metabolites were evaluated for their 
antibacterial activity against a panel of clinical isolates of multidrug-resistant (MDR) and 
methicillin-resistant Staphylococcus aureus (MICs 0.5-128 g/mL). Novel C15 eight-membered 
cyclic ethers101 with a characteristic terminal cis eneeyne moiety were isolated from the red 
alga, Laurencia glandulifera, collected from the Crete island in South Greece. These 
compounds exhibited antibacterial activity against MRSA strains with MICs of 8-256 g/mL.101  
A total of 17 diterpenes102 featuring the dolabellane skeleton were isolated  from the organic 
extracts of the brown alga, Dilophus spiralis. Some of these showed good antibacterial activity 
against six strains of S. aureus, including multidrug-resistant and methicillin-resistant 
variants.102  
Neomaclafungins A-I103, 26-membered macrolides of the oligomycin subfamily, were 
isolated from Actinoalloteichus sp. NPS702, a marine sediment collected from USA Bay, Kochi 
Prefecture, Japan. These macrolides exhibited significant antifungal activity in vitro against 
Trichophyton mentagrophytes (ATCC 9533) with MICs of 1-3 g/mL.103 
Polycyclic secondary metabolites, citreamicins A and B, citreaglycon A and 
dehydrocitreaglycon A,104 isolated from marine-derived Streptomyces caelestis exhibited 
antibacterial activity against Staphylococcus haemolyticus, S. aureus, and B. subtillis. 
Citreamicin A, citreamicin B, and citreaglycon A revealed strong activities against MRSA 
ATCC 43300 with MIC values of 0.25, 0.25, and 8.0 g/mL, respectively.104 
Isorhodoptilometrin-1-methyl ether, emodin, 1-methyl emodin, siderin, arugosin C, and 
variculanol obtained from the marine fungus A. versicolor were reported to exhibit antimicrobial 
activity, anticancer activity, and inhibition of Hepatitis C virus protease.105 A marine-derived 
fungus Nigrospora, produced anthraquinone derivative, 3-acetoxy-4-deoxybostrycin, which 
exhibited promising activity against Bacillus cereus (MIC 48.8 nM).106 C-glycosylated 
benz[]anthraquinone derivatives, urdamycinone E, urdamycinone G, dehydroxya- 
quayamycin, isolated from the marine Streptomycetes sp. displayedpotent activity against M. 
tuberculosis with MICs of 3.13-12.50 g/mL.107  
Trichodermaquinone and trichodermaxanthone from the marine-derived fungus 
Trichoderma aureoviride PSU-F95 demonstrated significant antibacterial activity against 
MRSA with MIC values of 8 and g/mL, respectively.108 Alkanoyl imidazoles, 
bulbimidazoles A-C,109 isolated from the culture extract of the gammaproteobacterium 
Microbulbifer sp. DC3-6 collected from a stony coral of the genus Tubastraea displayed broad-
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spectrum antimicrobial activity (MICs ranging from 0.78 to 12.5 μg/mL).109 Microketides A 
and B, a pair of C-11 epimeric polyketides, from the gorgonian-derived fungus 
Microsphaeropsis sp. RA10-14 collected from the South China Sea showed strong activity 
against Pseudomonas aeruginosa, Nocardia brasiliensis, Kocuria rhizophila, and Bacillus 
anthraci with the same MIC value as ciprofloxacin (0.19 μg/mL).110 The liquid culture of a 
Streptomyces sp. (strain BD21-2) collected from a shallow-water sediment sample from Kailua 
Beach, Oahu, Hawaii produced bonactin (51), which showed antimicrobial activity against 
both Gram-positive and Gram-negative bacterial as well as fungal strains.111 
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3.4 Antimicrobial natural products from animals 
Animals have also been reported to secrete compounds of biological interests 
including those with significant antimicrobial properties. These animals include amphibians 
species, mammals and similar animals capable of producing metabolites with promising 
biological activities. The skin glands of amphibians species have been documented to 
produce antimicrobial peptides (AMPs) that are crucial in the first line of defence against 
microbial invasion. The vast majority of AMPs isolated from the frog skin are reported to exert 
potent activity against antibiotic-resistant bacteria, protozoa, yeasts, and fungi by permeating 
and destroying the plasma membrane and inactivating intracellular targets. Importantly, since 
they do not bind to a specific receptor, AMPs are less likely to induce resistance mechanisms. 
Although most of the AMPs have common characteristics, they differ in amino acids 
sequences which produce a wide range bioactivity with varying degrees of efficacy. 
European fire-bellied toad, Bombina sps., is known to produce skin secretions with 
peptides, such as bombinins and bombinins H, with potential antimicrobial activity.112 
Bombinins and bombinins H, which are quite large peptides, were isolated from common 
precursors containing one or two bombinin copies at the amino and a single bombinin H at the 
carboxyl end.  Bombinins have showed activity against Gram-positive and Gram-negative 
bacteria and fungi but virtually inactive in haemolysis assays. However, bombinins H showed 
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lower bactericidal activities but lyse erythrocytes.112 Bombinins, identified from the ancient 
toad belonging to the genus Bombina, are a group of amphibian-derived peptides with broad-
spectrum antimicrobial activities. A novel bombinin precursor encoded a bombinin-like peptide 
(BLP-7) and a novel bombinin H-type peptide (Bombinin H-BO) were identified from the skin 
secretion of Oriental fire-bellied toad, Bombina orientalis.113 In the antimicrobial experiment, 
the synthetic replicate of BLP-7 exhibited more potency  than Bombinin H-BO against Gram-
positive and Gram-negative bacteria and yeast.  
A total of 11 AMPs was reported from Pleurodema somuncurence (Anura: 
Leptodactylidae: Leiuperinae). Three [Somuncurin-1 (FIIWPLRYRK), somuncurin-2 
(FILKRSYPQYY), and thaulin-3 (NLVGSLLGGILKK)]114 inhibited the growth of Escherichia 
coli but only Somuncurin-1 showed antibacterial activity against Staphylococcus aureus. In a 
biophysical membrane model, this peptide showed a greater permeation effect in prokaryotic-
like membranes and capability to restructure liposomes, suggesting fusogenic activity, which 
ultimate could cause cell aggregation and disruption of cell morphology. Eight new  peptides 
isolated from the skin secretion of the frog, Leptodactylus pustulatus,115 revealed structural 
similarities between them and other antimicrobial peptides reported from the same genus. 
Among these peptides, ocellatins-PT1 to -PT5 (25 amino acid residues) are amidated at the 
C-terminus, whilst ocellatins-PT6 to -PT8 (32 amino acid residues) have free carboxylates. 
All peptides, except for ocellatin-PT2, showed antibacterial activity against at least one Gram-
negative strain. Ocellatin-PT8 inhibited the growth of Staphylococcus aureus,  Escherichia 
coli, Klebsiella pneumoniae, and Salmonella choleraesuis strains with MICs of 60-240 μM.  An 
LC-MS-MS to analysis on the skin samples of Hypsiboas pulchellus, an Argentinian wild frog,   
has identified antimicrobial peptides with molecular mass within 1000-2000 Da.116 Out of 23 
novel sequences identified by MS three (named P1-Hp-1971, P2-Hp-1935, and P3-Hp-1891) 
were synthesised. These three AMPs inhibited the growth of Gram-positive Staphylococcus 
aureus (MICs of P1-Hp-1971, P2-Hp-1935, and P3-Hp-1891:  8, 66, and 17 μM, respectively) 
and Gram-negative E. coli (MICs of P1-Hp-1971, P2-Hp-1935, and P3-Hp-1891: 16, 33, and 
17 μM, respectively) revealing that P1-Hp-1971 and P3-Hp-1891 were the most 
active peptides.116  
Chitosan, a polycationic biopolymer naturally present in the exoskeletons of 
crustaceans and arthropods, has been used as food preservative because of their ability to 
suppress fungal colony growth and inhibit fungal spore germination at a 0.01% (w/v) 
concentration. 117 Its antibacterial activity evaluated against several Gram-negative (E. coli, P. 
fluorescens, S. Typhimurium, Vibrio parahaemolyticus) and Gram-positive bacteria (L. 
monocytogenes, Bacillus megaterium, B. cereus, S. aureus) 118 revealed that chitosan 
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inhibited the growth of most of the tested bacteria showing stronger bactericidal effects against 
Gram- positive bacteria than Gram-negative bacteria at a concentration of 0.1% in agar 
medium. An investigation on the antimicrobial activity of a chitosan against various food 
poisoning and food spoilage bacteria revealed that the chitosan mixture retarded the growth 
of Salmonella spp. and reduced the population of Staphylococcus spp. in raw milk. 119 A study 
conducted  to determine the shelf-life of oysters stored at 5±1C established that chitosan at 
a concentration of 5.0 mg/mL extended the shelf-life of oysters from 8-9 days to 14-15 days 
which indicated the great potential of chitosan for seafood preservation.120 
Lactoferrin, an iron-binding glycoprotein present in the milk of human and mammals, 
has shown to  have significant antimicrobial activity against a wide range of bacteria and 
viruses.121 Its antimicrobial activity has been reported against foodborne microorganisms 
including Carnobacterium, L. monocytogenes, E. coli, and Klebsiella122 with a reduction of 4 
log CFU/mL of Cronobacter species in the presence of 2.5 mg/mL lactoferrin in 0.2% peptone 
water within 4 h incubation at 37C. In combination with  nisin (0.1 mg/g),  lactoferrin (0.2 
mg/g)  displayed a significant reduction in spoilage bacterial counts (total aerobic bacteria, 
coli- form, E. coli, total psychrophilic bacteria, Pseudomonas species, yeast and moulds) and 
extend shelf-life of up to 10 days in meatballs.123 Milk-derived casein and whey proteins are 
known to possess various biological activities  including antimicrobial activities.124,125 
Casocidin, a peptide produced by hydrolysis of aS2-casein by chymosin, revealed 
antibacterial activity against Staphylococcus spp., Sarcina spp., B. subtilis, Diplococcus 
pneumoniae, and Streptococcus pyogenes.124 Isracidin, another casein derived peptide, 
showed antibacterial activity against S. aureus, L. monocytogenes, and C. albicans.125 
Peptides such as casein A and B at 0.05 mM and 0.22 mM respectively, were shown to inhibit 
the growth of pathogenic Enterobacter sakazakii. 126 Peptides generated from aS2- casein, 
aS1-casein, and k-casein have shown antibacterial effects against E. coli and B. subtilis.127 
The whey protein of bovine milk is composed of mainly of - lactoglobulin and -lactalbumin. 
The peptides released during the digestion of -lactoglobulin with trypsin has shown to 
possess antimicrobial activity against food- borne pathogens such as S. aureus, L. 
monocytogenes, Salmonella spp. and E. coli O157 at concentration of 10-20 mg/mL. 124,128  
4. Antimicrobial compounds in preclinical and clinical trials  
 
There are over 50 new antibiotics which are currently at different stages in clinical trials 
with the potential to treat serious bacterial infections including those which developed 
resistance to the existing antibiotics. A majority of these are of synthetic and/ or semi-synthetic 
origin. Among the antimicrobial agents originated from natural sources, which are undergoing 
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preclinical and clinical development stages are mostly antimicrobial peptides (AMPs)129 and 
are usually derived from microorganisms or animal sources. Some of these AMPs with 
potential antimicrobial activity and proven mechanism actions have been outlined below.  
MU1140, a lantibiotic peptide isolated from Streptococcus mutans, is currently 
undertaking preclinical development by Oragenics, Inc. It has been proven to exert activity 
against all gram‐positive bacteria, especially methicillin‐resistant S. aureus (MRSA). It acts 
through not only membrane disruption, but also inhibition of cell wall biosynthesis.130  
Arenicin (AP139) isolated from lugworm Arenicola marina consists of 21‐residue 
peptide, which has a positively charged amphipathic β‐hairpin structure linked with one 
disulfide bond. This is undergoing through preclinical trial by Adenium Biotech. It reveals 
bactericidal activity against multidrug‐resistant gram‐negative bacterial infections by 
membrane pore formation. 131  
EA‐230, developed by Exponential Biotherapies, is a linear tetrapeptide derived from 
the β‐chain of the human chorionic gonadotropin hormone (β‐hCG). The mode of action is 
known to be immunomodulation, such as the release of pro‐inflammatory cytokines and a 
reduction of neutrophil influx. It has demonstrated anti‐inflammatory activity when injected 
intravenously. Clinical trials for acute systemic inflammation (e.g., sepsis) and inflammation 
caused by organ dysfunction (e.g., acute kidney injury) are undergoing.132 
PAC113, developed by Pacgen Biopharmaceuticals, is a 12‐amino acid linear peptide 
derived from histatin 5, a human salivary α‐helical peptide. It exerts antimicrobial activity via 
membrane disruption, as well as immunomodulation. The phase II clinical trial has been 
completed treatment for oral candidiasis in HIV patients through mouth rinse.133 
Novexatin (NP213), developed by Novabiotics, is a cyclic cationic peptide consisting 
of seven arginine residues. It is going through the phase IIb clinical trial for the treatment of 
fungal nail infections with topical administration. It exerts its action through membrane 
disruption.133  
PXL01, a macrocyclic peptide comprised of 25 amino acids connected through a 
disulfide bond, is derived from human lactoferrin which is currently being evaluated by 
ProMore Pharma. It showed antimicrobial activity for the topical treatment of postsurgical 
adhesions and scar prevention. It acts through an immunomodulatory mechanism (e.g., 
inhibition of the release of pro‐inflammatory cytokines).132  
 
 
 
32 
Ramoplanin (NTI‐851), developed by Nano‐therapeutics, is a macrocyclic 
glycolipodepsipeptide produced by Actinoplanesspp. It reveals bactericidal activity by blocking 
the cell wall peptidoglycan synthesis of gram‐positive bacteria. Its phase III clinical study of 
the peptide was initiated for the oral treatment of vancomycin‐resistant enterococcus (VRE) 
colonization and also its phase II trial against Clostridium difficile.134  
5. Conclusions 
Nature continues to produce metabolites of chemical diversity with a large array of 
potential biological activities, which have contributed significantly in drug discovery including 
the development of new antibiotics. A vast majority of today’s antibiotics available for clinical 
uses are either derived directly from natural sources or their semisynthetic analogues. 
However, the global crisis of antimicrobial resistance urges the development of new 
antibiotics, which could fight against the so-called ‘superbugs’ escaping the lethal actions of 
existing antibiotics. Such superbugs raising alarming situation of AMR have been grouped 
together and acronymically dubbed as ESKAPE pathogens including multi-drug resistance 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter species.135 These ESKAPE 
pathogens require immediate attention of antimicrobial drug discovery groups around the 
world to find new and safe antibiotics in order to control the situation of global healthcare 
threat. Collaborative research approaches among both academic and industrial scientists 
including natural product chemists, medicinal chemists, microbiologist and biotechnologists 
are also much needed.  
Besides the discovery of new antibiotics, it is the responsibility of healthcare 
professionals and general public to preserve the efficacy of currently available antibiotics by 
raising public awareness on the appropriate uses of antibiotics. Although there has been a 
significant amount of work carried out through antibiotics stewardship, further work is 
necessary to encourage the reduction of over prescriptions and misuses of antibiotics. AMR 
situation is even much worse in the developing countries, where such situation could  be 
improved by educating the general public for appropriate uses of antibiotics and also alerting 
the physicians to be more careful in prescribing antibiotics.  
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18. Sköld, O. Drug Resistance Updates 2000, 3(3), 155-160.  
19. Kardos, N.; Demain, A. L. Appl. Microbiol. Biotechnol. 2011, 92 (4), 677–687. 
20. Bergeron, M. G.; Brusch, J. L.; Barza, M.; Weinstein, L. Antimicrob. Agents 
Chemother. 1973, 4(4), 396-401. 
21. Levine, D. P. Clinical Infectious Diseases, 2006, 42 (1), S5-12. 
22. Chopra, I.; Roberts, L. Microbiol. Mol. Biol. Rev. 2001, 65(2), 232-260. 
doi: 10.1128/MMBR.65.2.232-260.2001 
23. Pongs, O. (1979). "Chapter 3: Chloramphenicol". In Hahn, eFred E. (ed.). Mechanism of 
Action of Antibacterial Agents. Antibiotics Volume V Part 1. Berlin, Heidelberg: Springer 
Berlin Heidelberg. pp. 26–42.  
24. Berendsen, B.; Stolker, L.; de Jong, J,; Nielen, M.; Tserendorj, E.; Sodnomdarjaa, R.; 
Cannavan, A.; Elliott, C. Anal. Bioanal. Chem. 2010, 397(5),1955-63. doi: 
10.1007/s00216-010-3724-6. 
25. World Health Organisation (2019). World Health Organization model list of essential 
medicines: 21st list 2019. Geneva: World Health Organization.  
26. Caffrey, P.; Lynch, S.; Flood, E.; Finnan, S.; Oliynyk, M. Chem. Biol. 2001, 8(7), 713–
723. doi:10.1016/S1074-5521(01)00046-1. 
27. O'Keeffe, J.; Doyle, S.; Kavanagh, K. J. Pharmacy Pharmacol. 2003, 55(12), 1629–
1633. doi:10.1211/0022357022359 
28. Gupta, A. K.; Tomas, E. Dermatol. Clin,  2003, 21(3), 565-576. 
29. Mandell, G.; Bennett, J.; Dolin, R., Principles and practice of infectious diseases. 4 ed.; 
Churchill Livingstone: New York, 1995. 
30. Mingeot-Leclercq, M.-P.; Glupczynski, Y.; Tulkens, P. M. Antimicrob. Agents Chemother. 
1999, 43(4), 727-737.  
31. Denning, D. W.  J. Antimicrob. Chemother. 1997, 40, 611–614. 
32. Trookman, N. S.; Rizer, R. L.; Weber, T. J. American Academ Dermatolog. 2011, 64(3 
Suppl), S8-15. doi:10.1016/j.jaad.2010.11.011 
33. Benedict,  R. G.; Langlykke,  A. F.  J. Bacteriol., 1947, 54, 24. 
34. Falagas,  M. E.; Rafailidis,  P. I.; Matthaiou,  D. K.  Drug Resist Update, 2010, 13, 132–
138. doi:10.1016/j.drup.2010.05.002. 
35. Waksman, S. A.; Lechevalier, H. A. (March 1949). Science, 1949, 109, 305–307. 
 
 
 
35 
36. Gupte, M.; Kulkarni, P.; Ganguli, B. N. Appl. Microbiol. Biotechnol. 2002, 58(1), 46–
57. doi:10.1007/s002530100822 
37. Hammond, S. M.. Progress in Medicinal Chemistry. 1977, 14, 105–179.   
38. Liu, W-B.; Shi, Y.; Yao, L-L.; Zhou, Y.; Ye, B-C. (2013-01-01). PLOS One. 2013, 8 (11),  
e80676.  
39. Sensi, P. Rev. Infect. Dis., 1983, 5(Suppl. 3), S402-406. 
40. Calvori, C.; Frontali, L.; Leoni, L.; Tecce, G. Nature, 1965, 207(995), 417–
818. doi:10.1038/207417a0 
41. Fischer, J.; Ganellin, C. R. Analogue-based Drug Discovery. John Wiley & Sons, 2006. 
42. Shomura, T.; Ezaki, N.; Tsuruoka, T.; Niwa, T.; Akita, E.; Niida, T. J. Antibiotics. 1970, 
23(3), 155-161. 
43. Zárate, S. G.; De la Cruz Claure, M. L.; Benito-Arenas, R.; Revuelta, J.; Santana, A. G.; 
Bastida, A. Molecules 2018, 23(2), article number: 
284.  https://doi.org/10.3390/molecules23020284 
44. Pogliano, J.; Pogliano, N; Silverman, J. A. J. Bacteriol. 2012, 194(17), 4494–
504. doi:10.1128/JB.00011-12 
45. Guay, D. R. Consult Pharm. 2004, 19(7), 614-628. 
46. Wang, J.; Soisson, S. M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; 
Parthasarathy, G.; Tang, Y. S.; Cummings, R.; Ha, S.; Dorso, K.; Motyl, M.; Jayasuriya, 
H.; Ondeyka, J.; Herath, K.; Zhang, C.; Hernandez, L.; Allocco, J.; Basilio, A.; Tormo, J. 
R.; Genilloud, O.; Vicente, F.; Pelaez, F.; Colwell, L.; Lee, S. H.; Michael, B.; Felcetto, T.; 
Gill, C.; Silver, L. L.; Hermes, J. D.; Bartizal, K.; Barrett, J.; Schmatz, D.; Becker, J. W.; 
Cully, D.; Singh, S. B. Nature 2006, 441, 358-61. 
47. Martens, E.; Demain, A. L. J. Antibiot., 2011, 64(11), 705-710. doi: 10.1038. 
48. Arqués, J. L.; Rodríguez, E.; Nuñez, M.; Medina, M. J. Dairy Sci. 2008, 91, 70-75.  
49. Talarico, T. L.; Casas, I. A.; Chung, T. C.; Dobrogosz, W. J. Antimicrob. Agents 
Chemother. 1988, 32(12), 1854–1858.   
50. Kabuki, T.; Saito, T.; Kawai, Y.; Uemura, J.; Itoh, T. Int. J. Food Microbiol. 1997, 34(2), 
145–56. doi:10.1016/s0168-1605(96)01180-4 
51. Gänzle, M. G.; Höltzel, A.; Walter, J.; Jung, G.; Hammes, W. P. Appl. Environmental 
Microbiol. 2000, 66(10),  4325–4333. 
52. Pohanka, A.; Levenfors, J.; Broberg, A. Antimicrobial dialkyl resorcinols from 
Pseudomonas sp. Ki19. J. Nat. Prod. 2010, 73, 825-830.  
53. Ondeyka, J. G.; Zink, D. L.; Young, K.; Painter, R.; Kodali, S.; Galgoci, A.; Collado, J.; 
Tormo, J. R.; Basilio, A.; Vicente, F.; Wang, J.; Singh, S. B. J. Nat. Prod., 2006, 69, 377–
380. 
 
 
 
36 
54. Du, X.; Lu, C.; Li, Y.;  Zheng, Z.; Su, W.; Shen, Y. J. Antibiot., 2008, 61, 250-253. 
55. Hashizume, H.; Igarashi, M.; Hattori, S.;  Hori, M.; Hamada, M.; Takeuchi, T.  J. Antibiot., 
2001, 54, 1054–1059.  
56. Neuhof, T.; Schmieder, P.; Preussel, K.; Dieckmann, R.; Pham, H.; Bartl, F.; von Döhren, 
H. J. Nat. Prod., 2005, 68, 695–700.  
57. Neuhof T, Schmieder P, Seibold M, Preussel K, von Döhren H., Bioorg. Med. Chem. Lett., 
2006, 16, 4220–4222.  
58. Ling, L. L.; Schneider, T.; Peoples, A. J.; Spoering, A. L.; Engels, I.; Conlon, B. P.; Mueller, 
A.; Schäberle, T. F.; Hughes, D. E.; Epstein, S.; Jones, M.; Lazarides, L.; Steadman, V. 
A.; Cohen, D. R.; Felix, C. R.; Fetterman, K. A.; Millett, W. P.; Nitti, A. G.; Zullo, A. M.; 
Chen, C.; Lewis, K. Nature. 2015, 517(7535), 455-459. doi: 10.1038/nature14098. 
59. Jad, Y. E.; Acosta, G. A.; Naicker, T.; Ramtahal, M.; El-Faham, A.; Govender, T.; Kruger, 
H. G.; de la Torre, B. G.; Albericio, F. Org. Lett. 2015, 17, 6182-6185.  
60. Zaher, A. M.; Makboul, M. A.; Moharram, A. M.; Tekwani, B. L.; Calderón, A. I. J. 
Antibiot. 2015, 68,197-200. 
61. Essig, A.; Hofmann, D.; Münch, D.; Gayathri, S.; Künzler, M.; Kallio, P. T.; Sahl, H. G.; 
Wider, G.; Schneider, T.; Aebi, M. J. Biol. Chem. 2014, 289, 34953-34964. 
62. Cociancich, S.; Pesic, A.; Petras, D.; Uhlmann, S.; Kretz, J.; Schubert, V.; Vieweg, L.; 
Duplan, S.; Marguerettaz, M.; Noëll, J.; Pieretti, I.; Hügelland, M.; Kemper, S.; Mainz, A.; 
Rott, P.; Royer, M.; Süssmuth, R. D. Nat. Chem. Biol. 2015, 11, 195-197. doi: 
10.1038/nchembio.1734. 
63. Baumann, S.; Herrmann, J.; Raju, R.; Steinmetz, H.; Mohr, K. I.; Hüttel, S.; Harmrolfs, K.; 
Stadler, M.; Müller, R. Angew. Chem. Int. Ed. Engl. 2014, 53, 14605-14609. 
64. Heinrich, M.; Barnes, J.; Prieto-Garcia, J. M.;  Gibbons, S.; Williamson, E. Fundamentals 
of Pharmacognosy and Phytotherapy; 3rd ed; Elsevier: London, 2018. 
65. Gautam, R.; Saklani, A.; Jachak, S. M. J. Ethnopharmacol. 2007, 110, 200-234.  
66. Wang, Z.; Yu, P.; Zhang, G.; Xu, L.; Wang, D.; Wang, L.; Zeng, X.; Wang, Y. Bioorg. Med. 
Chem. 2010, 18, 4269-4274.  
67. Burt, S. Int. J. Food Microbiol. 2004, 94, 223-253. 
68. Azzouz, M. A.; Bullerman, L. B. J. Food Prot. 1982, 45, 1298-1301.  
69. Conner, D. E., Beuchat, L. R. J. Food Sci. 1984, 49, 429-434. 
70. Soliman, K. M.; Badeaa, R. I. Food Chem. Toxicol. 2002, 40,1669-1675. 
71. Pinto, E.; Vale-Silva, L.; Cavaleiro, C.; Salgueiro, L. J. Med. Microbiol. 2009, 58, 1454-
1462.  
72. Farag, D.S.; Daw, Z. Y.; Hewedi, F. M.; El-Baroty, G. S. J. Food Prot. 1989, 52, 665-667. 
 
 
 
37 
73. Schempp, C. M.; Pelz, K.; Wittmer, A.; Schopf, E.; Simon, J. C. Lancet 1999, 353, 2129.  
74. Gibbons, S.; Ohlendorf, B.; Johnsen, I. Fitoterapia 2002, 73, 300-304.  
75. Shiu, W. K. P.; Gibbons, S. Phytochem. 2006, 67, 2568-2572.  
76. Shiu, W. K. P.; Rahman, M. M.; Curry, J.; Stapleton, P.; Zloh, M.; Malkinson, J. P.; 
Gibbons, S. J. Nat. Prod. 2012, 75, 336-343.  
77. Osman, K.; Evangelopoulos, D.; Basavannacharya, C.; Gupta, A.; McHugh, T. D.; Bhakta, 
S.; et al.. Int. J. Antimicrob. Agents 2012, 39,124-129.  
78. Wang, W.; Zeng, Y. H.; Osman, K.; Shinde, K.; Rahman, M. M.; Gibbons, S.; Mu, Q. J. 
Nat. Prod. 2010, 73, 1815-1820.  
79. Rahman, M. M.; Shiu, W. K. P.; Gibbons, S.;  Malkinson, J. P. J. Nat. Prod. 2012, 75, 336-
343.  
80. Pessini, G. L.; Dias Filho, B. P.; Nakamura, C. V.; Cortez, D. A. G. Mem. Inst. Oswaldo 
Cruz, Rio de Janeiro, 2003, 98, 1115–1120.  
81. Rahman, M. M.; Gibbons, S.; Gray, A. I. Phytochem. 2007, 68, 1692-1697.  
82. Rahman, M. M.; Sarker, S. D.; Byres, M.; Gray, A. I. J. Nat. Prod. 2004, 67, 402-406.  
83. Rahman, M. M.; Khondkar, P.; Gray, A. I.; Sarker, S. D. Pharm. Biol. 2008, 46, 356-359.  
84. Sathiamoorthy, B. ; Gupta, P.; Kumar, M.; Chaturvedi, A. K.; Shukla, P. K.; Maurya, R. 
Bioorg. Med. Chem. Lett., 2007, 17, 239–242. 
85. Singh, D. N.; Verma, N. ; Raghuwanshi, S.; Shukla, P. K.; Kulshreshtha, D. K. Bioorg. 
Med. Chem. Lett., 2006, 16, 4512– 4514.  
86. Mskhiladze, L.; Kutchukhidze, J.;  Chincharadze, D.; Delmas, F.;  Elias, R.; Favel, A.  
Georgian Med. News, 2008, 154, 39–43. 
87. Zhang, J.-D.; Xu, Z.; Cao, Y.-B.; Chen, H.-S.; Yan, L.; An, M.-M.; Gao, P.- H.; Wang, Y.; 
Jia, X.-M.; Jiang, Y.-Y. J. Ethnopharmacol., 2006, 103, 76–84. 
88. Zhang, Y.; Li, H.-Z.; Zhan, Y.-J.; Jacob, M. R.; Khan, S. I.; Li, X.-C.; Yang, C.-R. Steroids, 
2006, 71, 712–719. 
89. Jensen, P. R., Fenical, W. Nat. Chem. Biol. 2006, 2, 666–673.  
90. Lam, K. S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. 
Microbiol. 2006, 9, 245–251.  
91. Jang, K. H., Nam, S. J., Locke, J. B., Kauffman, C. A., Beatty, D. S., Paul, L. A., Fenical, 
W. Angew. Chem. Int. Ed. Engl. 2013, 52, 7822–7824.  
92. Alt, S.; Wilkinson, B. ACS Chem. Biol. 2015, 10(11), 2468–2479. 
93. Moore, B. S.; Trischman, J. A.; Seng, D.; Kho, D.; Jensen, P. R.; Fenical, W. J. Org. Chem. 
1999, 64, 1145–1150.  
94. Miao, S.; Anstee, M. R.; LaMarco, K.; Matthew, J.; Huang, L. H. T.; Brasseur, M. M. J. Nat. 
Prod. 1997, 60, 858–861.  
 
 
 
38 
95. Hassan, H. M.; Degen, D.; Jang, K. H.; Ebright, R. H.; Fenical, W. J. Antibiot. 2015, 68(3), 
206-9.  
96. Son, S.; Ko, S. K.; Jang, M.; Lee, J. K.; Ryoo, I. J.; Lee, J. S.; Lee, K. H.; Soung, N. K.; 
Oh, H.; Hong, Y. S.; Kim, B. Y.; Jang, J. H.; Ahn, J. S. Org. Lett. 2015, 17(16), 4046-4049.  
97. Ding, L.; Maier, A.; Fiebig, H. H.; Lin, W. H.; Peschel, G.; Hertweck, C. J. Nat. Prod. 2012, 
75, 2223-2237.  
98. Smyrniotopoulos, V.; Vagias, C.; Rahman, M. M.; Gibbons, S.; Roussis, V. Chem. 
Biodivers. 2010, 7, 666-676. 
99. Smyrniotopoulos, V.; Vagias, C.; Rahman, M. M.; Gibbons, S.; Roussis, V. Chem. 
Biodivers. 2010, 7, 186-195. 
100. Smyrniotopoulos, V.; Vagias, C.; Rahman, M. M.; Gibbons, S.; Roussis, V. J. Nat. 
Prod. 2008, 71, 1386-1392.  
101. Kladi, M.; Vagias, C.; Stavri, M.; Rahman, M. M.; Gibbons, S.; Roussis, V. Phytochem. 
Lett. 2008, 1, 31-36. 
102. Ioannou, E.; Quesada, A.; Rahman, M. M.; Gibbons, S.; Vagias, C.; Roussis, V. J. Nat. 
Prod. 2011, 74, 213-222. 
103. Sato, S.; Iwata, F.; Yamada, S.; Katayama, M. J. Nat. Prod. 2012, 75, 1974-1982.  
104. Liu, L. L.; Xu, Y.; Han, Z.; Li, Y. X.; Lu, L.; Lai, P. Y.; Zhong, J. L.; Guo, X. R.; Zhang, 
X. X.; Qian, P. Y. Mar. Drugs 2012, 10, 2571-2583. 
105. Hawas, U. W.; El-Beih, A. A.; El-Halawany, A. M. Arch. Pharm. Res. 2012, 35, 1749-
1756. 
106. Yang, K. L.; Wei, M. Y.; Shao, C. L.; Fu, X. M.; Guo, Z. Y.; Xu, R. F.; Zheng, C. J.; She, 
Z. G.; Lin, Y. C.; Wang, C. Y. J. Nat. Prod. 2012, 75, 935-941. 
107. Supong, K.; Thawai, C.; Suwanborirux, K.; Choowong, W.; Supothina, S.; 
Pittayakhajonwut, P. Phytochem. Lett. 2012, 5, 651-656.  
108. Khamthong, N.; Rukachaisirikul, V.; Tadpetch, K.; Kaewpet, M.; Phongpaichit, S.; 
Preedanon, S.; Sakayaroj, J. Arch. Pharm. Res. 2012, 35, 461-468.  
109. Karim, M. R. U.; Harunari, E.; Oku, N.; Akasaka, K.; Igarashi, Y. J. Nat. Prod. 2020, 
83, 1295-1299. 
110. Liu, Y. F.; Zhang, Y. H.; Shao, C. L.; Cao, F.; Wang, C. Y. J. Nat. Prod. 2020, 83(4), 
1300-1304. 
111. Schumacher, R. W.; Talmage, S. C.; Miller, S. A.; Sarris, K. E.; Davidson, B. S.; 
Goldberg, A. J. Nat Prod. 2003, 66(9),1291-1293. 
112. Simmaco, M.; Kreil, G.; Barra, D. Biochim. Biophys. Acta. 2009, 788(8),1551-1555. 
113. Zhou, C.; Wang, Z.; Peng, X.; Liu, Y.; Lin, Y.; Zhang, Z.; Qiu, Y.; Jin, M.; Wang, R.; 
Kong, D. Chem. Biol. Drug Des. 2018, 91(1), 50-61.  
 
 
 
39 
114. Cancelarich, N. L.; Wilke, N.; Fanani, M. A. L.; Moreira, D. C.; Pérez, L. O.; Alves 
Barbosa, E.; Plácido, A.; Socodato, R.; Portugal, C. C.; Relvas, J. B.; de la Torre, B. G.; 
Albericio, F.; Basso, N. G.; Leite, J. R.; Marani, M. M. J. Nat. Prod. 2020, 83(4), 972-984. 
doi: 10.1021/acs.jnatprod.9b00906. 
115. Marani, M. M.; Dourado, F. S.; Quelemes, P. V. de Araujo, A. R.; Perfeito, M. L.; 
Barbosa, E. A.; Véras, L. M.; Coelho, A. L.; Andrade, E. B.; Eaton, P.; Longo, J. P.; 
Azevedo, R. B.; Delerue-Matos, C.; Leite, J. R. J. Nat. Prod. 2015, 78(7),1495-504. doi: 
10.1021/np500907t. 
116. Siano, A.; Húmpola, M. V.; de Oliveira, E.; Albericio, F.; Simonetta, A. C.; Lajmanovich, 
R.; Tonarelli, G. G. J. Nat. Prod. 2014, 77(4), 831-841. doi: 10.1021/np4009317.  
117. Tikhonov, V. E.; Stepnova, E. A.; Babak, V. G.; Yamskov, I. A.; Palma- Guerrero, J.; 
Jansson, H-B.; Lopez-Llorca, L. V.; Gerasimenko, D. V.; Avdienko , I. D.; Varlamov, V. P. 
Carbohydr. Polym. 2006, 64, 66-72. 
118. No, H. K.; Young Park, N.; Ho Lee, S.; Meyers, S. P. (2002). Int. J. Food Microbiol., 
2002, 74(1), 65-72. 
119. Tsai, G.-J.; Wu, Z.-Y.; Su, W.-H. (2000). J. Food Protect., 2000, 63(6), 747-752. 
120. Cao, R.; Xue, C.-H.; Liu, Q. (2009). Int. J Food Microbiol., 2009, 131(2), 272-276. 
121. Lönnerdal, B. (2011). Nestle Nutrition Workshop Ser. Paediatric Programme, 2011, 
67, 41-54. 
122. Al-Nabulsi, A. A.; Holley, R. A. (2005, Food Microbiol., 22(2), 179-187. 
123. Colak, H.; Hampikyan, H.; Bingol, E. B.; Aksu, H. (2008). 2008, J. Food Safety, 28(3), 
355-375.  
124. Szwajkowska, M.; Wolanciuk, A.; Barłowska, J.; Krol, J.; Litwinczuk, Z. Animal Sci 
Papers Rep. 2011, 29(4), 269-280. 
125. Korhonen, H. J.; Rokka, S.. Properties and applications of antimicrobial proteins and 
peptides from milk and eggs. In (Hettiarachchy, N.S.; Sato, K.; Marshall, M.R.; Kannan, A. 
eds.) Bioactive food proteins and peptides: Applications in human health, 2012. 
126. Hayes, M.; Ross, R.; Fitzgerald, G.; Hill, C.; Stanton, C. Appl. Environ. Microbiol, 2006, 
72(3), 2260-2264. 
127. Elbarbary, H.  A.; Abdou, A. M.; Nakamura, Y.; Park, E. Y.; Mohamed, H. A.; Sato, K. 
Biofactors, 2012, 38(4), 309-315. 
128. Demers-Mathieu, V.; Gauthier, S. F.; Britten, M.; Fliss, I.; Robitaille, G.; Jean, J. Int. 
Dairy J. 2012, 28(2), 94-101.  
129. Koo, H. B.; Seo, J. Peptide Sci. 2019, 111, e24122. 
130. Chen, S.; Wilson-Stanford, S.; Cromwell, W.; Hillman, J. D.; Guerrero, A.; Allen, C. A.; 
Smith, L. Appl. Environ. Microbiol. 2013, 79, 4015-4023. 
 
 
 
40 
131. Shenkarev, Z. O.; Balandin, S. V.; Trunov, K. I.; Paramonov, A. S.; Sukhanov, S. V.; 
Barsukov, L. I.; Ovchinnikova, T. V.  Biochem. 2011, 50, 6255-6256. 
132. Wiig, M.; Olmarker, K.; Hakansson, J.; Ekstrom, L.; Nilsson, E.; Mahlapuu, M. J. Hand 
Surg. Eur. Vol. 2011, 36, 656-662. 
133. Greber, K. E.; Dawgul, M. Curr. Top. Med. Chem. 2017, 17, 620-628. 
134. Res, Y.; Shin, D., Hwang, I. ; Boger, D. L. J. Am. Chem. Soc. 2004, 126, 1041-1043. 
135. Rice, L. B.. J. Infect. Dis. 2008, 197(8), 1079-1081. 
 
